• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Castle Biosciences Inc (NQ: CSTL )

    21.09 -0.44 (-2.04%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 303,144
    Open 21.23
    Bid (Size) 20.06 (1)
    Ask (Size) 22.06 (1)
    Prev. Close 21.53
    Today's Range 20.81 - 21.43
    52wk Range 9.260 - 26.70
    Shares Outstanding 25,167,365
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
    From Castle Biosciences Inc.
    Via Business Wire

    Performance

    YTD
    -3.96%
    -3.96%
    1 Month
    -5.21%
    -5.21%
    3 Month
    -14.62%
    -14.62%
    6 Month
    +48.21%
    +48.21%
    1 Year
    -7.30%
    -7.30%

    More News

    Read More
    Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
    From Castle Biosciences Inc.
    Via Business Wire
    Recap: Castle Biosciences Q4 Earnings
    Via Benzinga
    Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
    From Castle Biosciences Inc.
    Via Business Wire
    Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Castle Biosciences Inc.
    Via Business Wire
    Earnings Preview For Castle Biosciences
    Via Benzinga
    Castle Biosciences Announces Updates to its Board of Directors
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
    From Castle Biosciences Inc.
    Via Business Wire
    Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
    From Castle Biosciences Inc.
    Via Business Wire
    Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
    From Castle Biosciences Inc.
    Via Business Wire
    New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
    From Castle Biosciences Inc.
    Via Business Wire
    In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
    From Castle Biosciences Inc.
    Via Business Wire
    Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
    From Castle Biosciences Inc.
    Via Business Wire
    New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.